A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Exploratory Efficacy and Safety Study of SPD489 in Adults 18-55 Years With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant.

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Exploratory Efficacy and Safety Study of SPD489 in Adults 18-55 Years With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Lisdexamfetamine (Primary) ; Escitalopram
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Shire
  • Most Recent Events

    • 07 Jun 2012 Primary endpoint 'Montgomery-Asberg-Depression-Rating-Scale' has been met, according to results presented at the 28th International Congress of Collegium Internationale Neuro Psychopharmacologicum.
    • 07 Jun 2012 Results presented at the 28th International Congress of Collegium Internationale Neuro Psychopharmacologicum.
    • 01 Nov 2010 Results were reported in a Shire media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top